Blogging Stroke
Check out my review of the paper published in NEJM -Role of Combined Clopidogrel and Aspirin in High-Risk TIA and Stroke ow.ly/1Hle30l9Kjf
This is a landmark study for US population. Along with the CHANCE trial (specific to the Chinese population), this trial has changed the way we practice stroke. The latest 2019 AHA/AHA Guidelines for the Early Management of Patients With Acute Ischemic Stroke has changed the level of evidence to Class I-a for use of dual antiplatelet in patients with non-cardioembolic stroke.
In patients presenting with minor non-cardioembolic ischemic stroke (NIHSS score ≤3) who did not receive IV alteplase, treatment with dual antiplatelet therapy (aspirin and clopidogrel) started within 24 hours after symptom onset and continued for 21 days is effective in reducing recurrent ischemic stroke for a period of up to 90 days from symptom onset.
AHA/ASA 2019 Guidelines for Early management of acute ischemic stroke.
Tell us about your thoughtsWrite message